A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.

This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.